Methadone Clinics Loosened the Rules and Retention Jumped 17%. HHS's New Toolkit Buries That.

Rebecca Smith is 65 years old, a former medical assistant and a grandmother, and in the spring of 2024 she got put back on a leash. After she tested positive for alcohol metabolites at her grandson’s high school graduation party, her clinic in Detroit — the Tolan Park Research Clinic — pulled her off the two-week take-home schedule she’d earned and put her back on daily, in-person dosing. That meant an $8 Uber ride to the clinic and back, every single day, for medication she’d been taking safely for years. She lost her catering job. She fell behind on rent. “I want you to check me if I’m actually doing something wrong,” she told STAT News at the time. “This is not helping me in my recovery.”

That was the old methadone system — punitive by design, built to catch you failing rather than help you stay. Two years later, a national wave of reform aimed at ending exactly that pattern is showing real results. And this month, the federal government released a homelessness and addiction strategy that barely mentions the medication Rebecca Smith relies on to stay alive.

Evidence-based medication treatment works, retention data proves the reforms that expand it are working too, and HHS just published a national playbook that treats both facts as an afterthought.

That’s not a matter of interpretation. It’s what’s in the documents.

The reform HHS won’t talk about is already saving people

Start with what actually changed at the clinic level, because it’s the part of this story that gets buried under press-release language. During COVID, in 2020, SAMHSA gave methadone clinics emergency permission to hand patients weeks’ worth of medication to take home instead of requiring them to show up and drink it in front of a nurse every single morning — the practice known as take-home dosing. In 2024, federal regulators made that flexibility permanent through an update to the rule governing opioid treatment programs (the clinics that dispense methadone), and went further: they eliminated the requirement that a patient prove a full year of documented opioid addiction before starting treatment, dropped the rule that patients fail at least two other treatment attempts first, and stopped requiring counseling as a condition of getting medication.

Two years on, STAT News reporting published August 14 surveyed 241 opioid treatment programs — roughly one in ten of the programs operating nationally — and found clinics that adopted the reforms saw retention in treatment at the three-month mark rise by an average of 17%. More than 70% of responding clinics adopted at least half of the recommended changes, and roughly two-thirds of state regulators now let patients get counseling without it being forced on them as a precondition for medication. Mark Parrino, president of the American Association for the Treatment of Opioid Dependence, put it plainly: “A significant majority of OTPs have incorporated the changes… retention in treatment has significantly increased.” OTP is the clinical shorthand for opioid treatment program — a methadone clinic, in plain language.

At CompDrug, a clinic on the north side of Columbus, Ohio that sees more than 200 patients a day, CEO Dustin Mets has watched the culture shift from the inside. His clinic’s three-month retention rose in line with the national figure after loosening dosing rules and dropping mandatory counseling. His case for why is simple and, frankly, obvious to anyone who’s sat in a clinic waiting room: forcing someone to show up in person every day doesn’t prove they’re recovering, it just proves they can get a ride. “Physical presence,” Mets told STAT, “is a rather poor proxy for a strong therapeutic relationship.” Retention — staying in treatment — is one of the best predictors addiction medicine has for who survives. Seventeen percent more people staying in care at three months is not a rounding error. It is, by the standard metric this field uses to measure success, a genuine win, arriving in real time, on a national scale, for a treatment medication for opioid use disorder that federal policy has spent decades treating with suspicion instead of respect.

Seventeen percent more people staying in care at three months is not a rounding error.

What “Treatment First” actually does is smaller than what it claims

Two days before that data landed, on August 12, HHS Secretary Robert F. Kennedy Jr., HUD Secretary Scott Turner, and ONDCP Director Sara Carter stood at the San Diego Rescue Mission and unveiled the Best Practices Toolkit: Addressing Homelessness and Addiction Through Treatment First, a federal playbook for cities and counties dealing with homelessness and addiction together. “Treatment must come first,” Kennedy said. “Recovery begins when we connect people with effective care, not leave them trapped in addiction and homelessness.” Turner’s version of the same argument: “Housing is essential, but housing alone is not enough.”

Read that carefully, because the framing does a lot of quiet work. The toolkit explicitly rejects Housing First — the approach, backed by two decades of research, of giving someone stable housing without first demanding sobriety, on the theory that it’s very hard to get sober while sleeping outside. Instead it promotes conditional, accountability-driven programming: consistent schedules, employment integration, faith-inclusive services, and contingency management, the practice of paying people small rewards for testing negative for drugs — itself a legitimately evidence-backed tool, just one deployed here as a substitute for medication rather than alongside it. The toolkit prioritizes hiring people with lived recovery experience into program roles, which is also good policy on its own terms. And according to STAT’s reporting, it leans on a study claiming veterans placed in supportive housing had higher overdose mortality than a comparison group — using that finding to argue against unconditional housing access, rather than to argue for pairing housing with better addiction care.

What the toolkit does not do, in any real way, is talk about methadone or buprenorphine — the two medications with the strongest mortality-reduction evidence in all of addiction medicine, the ones doctors actually reach for first when someone is at risk of dying from opioid use. A federal strategy document for addressing homelessness and addiction that gives minimal space to the treatments most likely to keep an unhoused person with a substance use disorder alive is not a treatment strategy. It’s a values statement wearing a treatment strategy’s clothes. That gap isn’t accidental — the day after the toolkit launched, Kennedy continued on through California pressing the same message and blaming the prior administration’s approach for the state’s addiction and homelessness crisis, and the toolkit itself lands inside a broader policy push that has spent 2026 narrowing what harm reduction the federal government will pay for at all.

This is the same instinct that killed the needle exchange for twenty years

None of this is new. In 1988, Senator Jesse Helms attached a rider to the Health Omnibus Programs Extension — signed into law that November — banning any federal money from funding needle exchange programs, on the theory that handing someone a clean syringe was the government telling them it was fine to keep using. The ban held for 21 years. Congress lifted it in 2009, Republicans reattached it to a budget bill in December 2011, and it wasn’t lifted again — partially, and only for costs other than the syringes themselves — until December 2015. Meanwhile, the CDC estimates syringe exchanges reduce HIV and hepatitis C transmission among people who inject drugs by more than half. For most of three decades, Washington chose the symbolism of abstinence over a program that keeps people alive, and called that choice moral clarity.

The pattern is running again in 2026. That April, updated SAMHSA guidance stripped fentanyl and xylazine test strips — cheap paper strips that tell someone what’s actually in their drugs before they use them — out of the list of supplies federal grant dollars can pay for, along with sterile water and overdose hotlines aimed at people who are still using. In July, the HALT Fentanyl Act permanently classified fentanyl-related substances as controlled, hardening the enforcement side of the ledger. And now the Treatment First toolkit arrives to shrink the medication side of it too. Each of these is defensible in isolation as a values choice. Stacked together, they describe an administration that keeps finding reasons the cheap thing that keeps people alive “sends the wrong message” — the exact sentence, in spirit, that justified the syringe ban in 1988. Overdose deaths are falling — the CDC’s provisional count shows a roughly 12% drop for the year ending in February, down to an estimated 68,641 deaths nationally. That decline happened because more naloxone, more medication treatment, and yes, more harm reduction reached more people. Narrowing all three now is not a neutral policy adjustment layered on top of progress. It is a bet against the thing that produced the progress.

Overdose deaths are falling — the CDC’s provisional count shows a roughly 12% drop for the year ending in February, down to an estimated 68,641 deaths nationally.

The reforms that are working aren’t reaching everyone, and that’s on the industry too

Here’s where this gets complicated in a way that’s honest rather than convenient: the 17% retention gain is real, but it is not evenly distributed, and the toolkit isn’t the only obstacle standing between patients and better care. Adoption of the 2024 reforms tracks political geography — progressive-leaning states like New York are further along than conservative-leaning states, according to STAT’s survey — and even within reform-friendly states, plenty of clinics haven’t budged. Aaron Ferguson, an advocate with Liberate Methadone, pushed back hard on the rosy read of the data, arguing that larger providers in particular have resisted implementing the changes, so many patients still don’t feel any of the benefit. Rebecca Smith’s clinic, the one that put her back on daily dosing for a positive alcohol test two years ago, is a preview of what Ferguson means: the rule changed, but plenty of the people enforcing it didn’t.

If you’re a case manager reading this with a caseload of people on methadone or buprenorphine, don’t assume the 2024 reforms have reached your patients’ clinic just because they’re federal policy now — ask directly whether take-home dosing and non-mandatory counseling are actually being offered there, because Ferguson’s critique says you can’t take that for granted, and a patient who doesn’t know to ask will often just get told no. And do it this week rather than next: the CMS Medicaid work-requirement rule that took effect June 1 caps the substance-use-disorder exemption from work requirements at five years before those requirements start being enforced on January 1, 2027, and Georgetown’s Center for Children and Families has flagged that the documentation process for that exemption is murky enough that people will fall through by paperwork alone, not by ineligibility. Start that clock and that paper trail now, for every patient it applies to, before the enforcement date makes it urgent instead of routine.

What’s still yours, regardless of what Washington publishes

Here’s what doesn’t change no matter what a toolkit says or what a press conference in San Diego announces: methadone and buprenorphine still work, they are still available at clinics and prescribers across the country right now, and the clinical evidence for both keeping people alive hasn’t gotten weaker just because a federal document gave them a paragraph instead of a chapter. If you’re in treatment on medication today, that treatment is not political theater — it’s yours, it’s working the same way it was working last month, and a toolkit with your medication’s name barely in it doesn’t get to overrule your own body’s data. You know what staying in this specific kind of treatment has done for you better than anyone standing at a podium.

What changed this month isn’t the medicine. It’s that the agency responsible for public health just told the country, in an official federal document, that the medicine is optional — the same week a national data set said the opposite. Rebecca Smith didn’t need a press release to tell her that being punished for an honest mistake wasn’t helping her recovery; she said so herself, two years ago, to a reporter, on the record. The clinics that listened to people like her are the ones posting 17% better retention right now. The toolkit HHS just published isn’t built from that evidence. It’s built despite it.